Novel coronavirus SARS-CoV-2 has rapidly become a global public health emergency. Human angiotensin-converting enzyme II (ACE2) has been identified as a functional receptor for SARS-CoV-2. The lack of vaccine and antivirals has brought an urgent need for an animal model. Sun et al., have created a stable mouse model expressing human ACE2 (hACE2) by using CRISPR/Cas9 knock-in technology, replacing the endogenous mouse ACE2 (mACE2) with the human ACE2.
Their new model demonstrated that these hACE2 mice are highly susceptible to SARS-CoV-2 infection via intranasal inoculation. Infected mice developed interstitial pneumonia characterized by inflammatory cell infiltration, alveolar septal thickening, and distinctive vascular system injury, which recapitulated the clinical features in most COVID-19 patients. HUABIO Recombinant ACE Monoclonal Antibody, ET1705-36, was used in western blotting. Results showed that hACE2 expression was strong in lung and kidney but very weak in spleen and liver, which displayed a similar expression pattern of mACE2 protein in wild-type (WT) animals
The new model provides a useful tool for studying SARS-CoV-2 transmission and pathogenesis and evaluating COVID-19 vaccines and therapeutics.
Read More: A mouse model of SARS-CoV-2 infection and pathogenesis
View: Recombinant ACE Monoclonal Antibody
References:
1.) Sun, S. H., Chen, Q., Gu, H. J., Yang, G., Wang, Y. X., Huang, X. Y., ... & Guo, Y. (2020). A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host & Microbe.